Mechanistic Evaluation of Response in TRD (MERIT)

Completed · Phase 2 · Has a placebo group

Conditions studied: Treatment Resistant Depression, Major Depressive Disorder

In brief

To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.

Key facts

Study ID
NCT04608396
Run by
Axsome Therapeutics, Inc.
People needed
44
Starts
2020-08-13
Expected to finish
2021-07-30
Last updated by the study team
2022-07-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.